Metraipolis › archive › dc_4c0fed87f3d4

Hybutimibe, an innovative cholesterol absorption inhibitor for lipid-lowering therapy: current evidence and future perspectives — Europe PMC PMID:42898767

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42898767
DOI
10.3389/fphar.2026.1936459
License (as archived)
solo-consultazione
Archived
2026-11-01T08:04:57.332Z
SHA-256 of the archived text
f25a0874dfed959e404d2c2c3622648bc2dec33c04c4d01d41d8f071673eabe9
Stable URL of this page
https://metraipolis.com/documento/dc_4c0fed87f3d4

How to cite

Hybutimibe, an innovative cholesterol absorption inhibitor for lipid-lowering therapy: current evidence and future perspectives — Europe PMC PMID:42898767 — Europe PMC (en), https://europepmc.org/article/MED/42898767 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_4c0fed87f3d4 (Metraipolis archive dc_4c0fed87f3d4, sha256 f25a0874dfed959e404d2c2c3622648bc2dec33c04c4d01d41d8f071673eabe9)
BibTeX
@misc{dc4c0fed87f3d4,
  title = {Hybutimibe, an innovative cholesterol absorption inhibitor for lipid-lowering therapy: current evidence and future perspectives — Europe PMC PMID:42898767},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42898767},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_4c0fed87f3d4; sha256 f25a0874dfed959e404d2c2c3622648bc2dec33c04c4d01d41d8f071673eabe9},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42898767. Agents can read the archived copy with the MCP tool read_document.